PL2544657T3 - Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów - Google Patents

Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów

Info

Publication number
PL2544657T3
PL2544657T3 PL11709793T PL11709793T PL2544657T3 PL 2544657 T3 PL2544657 T3 PL 2544657T3 PL 11709793 T PL11709793 T PL 11709793T PL 11709793 T PL11709793 T PL 11709793T PL 2544657 T3 PL2544657 T3 PL 2544657T3
Authority
PL
Poland
Prior art keywords
amisulpride
vomiting
treating post
operative nausea
nausea
Prior art date
Application number
PL11709793T
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2544657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of PL2544657T3 publication Critical patent/PL2544657T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL11709793T 2010-03-11 2011-03-10 Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów PL2544657T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
EP11709793.1A EP2544657B1 (en) 2010-03-11 2011-03-10 Use of amisulpride for treating post-operative nausea and vomiting
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (1)

Publication Number Publication Date
PL2544657T3 true PL2544657T3 (pl) 2014-10-31

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
PL11709793T PL2544657T3 (pl) 2010-03-11 2011-03-10 Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
PL12188047T PL2567690T3 (pl) 2010-03-11 2011-03-10 Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
PL14173186T PL2796171T3 (pl) 2010-03-11 2011-03-10 Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12188047T PL2567690T3 (pl) 2010-03-11 2011-03-10 Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
PL14173186T PL2796171T3 (pl) 2010-03-11 2011-03-10 Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat

Country Status (26)

Country Link
US (12) US8686019B2 (pl)
EP (3) EP2796171B1 (pl)
JP (2) JP5886213B2 (pl)
KR (1) KR101738201B1 (pl)
CN (1) CN102892407B (pl)
AU (1) AU2011225898B2 (pl)
BR (1) BR112012022746B1 (pl)
CA (1) CA2792392C (pl)
CY (3) CY1115485T1 (pl)
DK (3) DK2567690T3 (pl)
EA (1) EA030335B1 (pl)
ES (3) ES2665418T3 (pl)
GB (1) GB201004020D0 (pl)
HR (3) HRP20140744T1 (pl)
HU (1) HUE037088T2 (pl)
IL (1) IL221746A (pl)
LT (1) LT2796171T (pl)
MX (3) MX388787B (pl)
NO (1) NO2796171T3 (pl)
NZ (1) NZ602279A (pl)
PL (3) PL2544657T3 (pl)
PT (3) PT2544657E (pl)
RS (3) RS53467B (pl)
SI (3) SI2796171T1 (pl)
SM (3) SMT201800188T1 (pl)
WO (1) WO2011110854A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP2018530744A (ja) 2015-09-02 2018-10-18 カリフォルニア インスティチュート オブ テクノロジー 低濃度の硫化水素ガスの分光学的検出のための方法および装置
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
KR20220041143A (ko) * 2019-07-31 2022-03-31 아스텔라스세이야쿠 가부시키가이샤 귀내 투여용의 의약 조성물
EP4175631A1 (en) 2020-07-06 2023-05-10 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
JP2026501286A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4735456A1 (en) 2023-06-30 2026-05-06 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CN101410094B (zh) 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
LT2796171T (lt) 2018-05-10
US10085970B2 (en) 2018-10-02
PT2567690E (pt) 2014-09-03
EP2544657A2 (en) 2013-01-16
NO2796171T3 (pl) 2018-06-30
PL2567690T3 (pl) 2014-11-28
US20210228543A1 (en) 2021-07-29
JP2013522181A (ja) 2013-06-13
IL221746A (en) 2017-03-30
PT2796171T (pt) 2018-04-24
NZ602279A (en) 2014-08-29
ES2665418T3 (es) 2018-04-25
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
US9545426B2 (en) 2017-01-17
JP6279526B2 (ja) 2018-02-14
US10525033B2 (en) 2020-01-07
SI2544657T1 (sl) 2014-12-31
CA2792392A1 (en) 2011-09-15
JP2016028090A (ja) 2016-02-25
EP2567690B1 (en) 2014-07-16
KR20130045241A (ko) 2013-05-03
CY1115485T1 (el) 2017-01-04
BR112012022746B1 (pt) 2021-09-28
HRP20140745T1 (hr) 2014-09-26
US9119836B2 (en) 2015-09-01
CN102892407A (zh) 2013-01-23
RS57032B1 (sr) 2018-05-31
MX2012010411A (es) 2012-11-30
DK2544657T3 (da) 2014-08-11
US9084765B2 (en) 2015-07-21
US9889118B2 (en) 2018-02-13
HRP20140744T1 (hr) 2014-09-26
US20150335616A1 (en) 2015-11-26
SI2796171T1 (en) 2018-05-31
CY1120170T1 (el) 2018-12-12
EP2544657B1 (en) 2014-07-16
MX388787B (es) 2025-03-20
ES2496099T3 (es) 2014-09-18
SI2567690T1 (sl) 2014-12-31
WO2011110854A2 (en) 2011-09-15
EA030335B1 (ru) 2018-07-31
GB201004020D0 (en) 2010-04-21
CY1115487T1 (el) 2017-01-04
BR112012022746A2 (pt) 2016-07-05
EP2796171B1 (en) 2018-01-31
PT2544657E (pt) 2014-09-03
US20250186394A1 (en) 2025-06-12
US20140147517A1 (en) 2014-05-29
DK2796171T3 (en) 2018-05-07
RS53466B (sr) 2014-12-31
JP5886213B2 (ja) 2016-03-16
EP2796171A1 (en) 2014-10-29
SMT201800188T1 (it) 2018-07-17
CN102892407B (zh) 2016-03-23
HRP20180436T1 (hr) 2018-05-04
US20180042896A1 (en) 2018-02-15
EP2567690A1 (en) 2013-03-13
HUE037088T2 (hu) 2018-08-28
AU2011225898B2 (en) 2014-07-03
SMT201400126B (it) 2015-05-05
DK2567690T3 (da) 2014-08-11
KR101738201B1 (ko) 2017-05-19
CA2792392C (en) 2018-06-19
RS53467B (sr) 2014-12-31
US20130022689A1 (en) 2013-01-24
US8686019B2 (en) 2014-04-01
US20200093792A1 (en) 2020-03-26
HK1179152A1 (zh) 2013-09-27
EA201290833A1 (ru) 2013-09-30
US20170087128A1 (en) 2017-03-30
MX370629B (es) 2019-12-18
US20220296570A1 (en) 2022-09-22
US20180353473A1 (en) 2018-12-13
ES2496092T3 (es) 2014-09-18
MX2019015396A (es) 2020-02-07
SMT201400127B (it) 2015-05-05
US12194022B2 (en) 2025-01-14
AU2011225898A1 (en) 2012-10-04
US20230144973A1 (en) 2023-05-11
US20130022688A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
PL2544657T3 (pl) Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
EP2523630A4 (en) SYSTEMS AND METHODS FOR BARIATRIC THERAPY
EP2603250A4 (en) Wound treatment and containment arrangement
IL226331A0 (en) Bromodomain inhibitors and their use
ZA201305495B (en) Compounds and their use as bace inhibitors
EP2549963A4 (en) Systems and methods for prostate treatment
ZA201303605B (en) Compounds and methods for treating pain
EP2571570A4 (en) APPARATUS AND ELECTROSTIMULATION FOR ARTHRITIS
EP2656301A4 (en) SYSTEMS AND METHODS FOR USING RISK AREAS
PL2576776T3 (pl) Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
SI2557084T1 (sl) Kalcijev rosuvastatin polizdelek in postopek za njegovo pripravo
ZA201208895B (en) Bicyclic compound derivatives and their use as acc inhibitors
EP2554528A4 (en) Coated granular body and method for producing coated granular body
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2566483A4 (en) METHOD AND MEANS FOR IMPROVED WOUND HEALING
EP2624854A4 (en) MOESIN MODULATORS AND ITS USES
WO2012057895A9 (en) Composition and method for treating wounds
GB201016486D0 (en) Compounds for the use in treatment of plants
AU2010904485A0 (en) Agents and Methods for Treating Hematologic Conditions
AU2010901243A0 (en) Security device and method of manufacture
AU2010904569A0 (en) Wealth and LoanCare
HK1187900A (en) Inhibitors of pi3k-delta and methods of their use and manufacture
HK1180935A (en) Systems and methods for prostate treatment
HK1184329A (en) Oligo-benzamide compounds and their use